SCHEMBL229151

SCHEMBL229151

O=C(c1ccc(F)cc1)C1(F)CCNCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
PTPN1 P18031 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
DPP4 P27487 1/20 0.38
MAOB P27338 1/20 0.38
OPRD1 P41143 1/20 0.38
MMP3 P08254 1/20 0.38
MMP10 P09238 1/20 0.38
RAB9A P51151 2/20 0.37
BCL2L1 Q07817 1/20 0.37
BAD Q92934 1/20 0.37
TNFRSF1A P19438 1/20 0.37
NPC1 O15118 1/20 0.36
HSD11B1 P28845 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRA5 P31644 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10524449 0.87 CES2 (0.50) CES2CES1PTPN1CA1CA2
Tert-Butyl Formate SCHEMBL27758592 0.85 MAOB (0.33) CES2CES1DPP4MAOBOPRD1
SCHEMBL18321798 0.84 SIGMAR1 (0.44) CES2CES1
SCHEMBL373783 0.83 HDAC1 (0.42) CES2CES1CA1CA2DPP4
SCHEMBL230343 0.82 CES2 (0.42) CES2CES1PTPN1CA1CA2
SCHEMBL24484742 0.81 CES2 (0.47) CES2CES1PTPN1MAOBMMP3
SCHEMBL227735 0.81 CES2 (0.41) CES2CES1PTPN1CA1CA2
Bromide SCHEMBL10966858 0.79 OPRD1 (0.40) CES2CES1PTPN1CA1CA2
SCHEMBL3974848 0.78 SLC6A2 (0.40) CES2CES1PTPN1CA1CA2
SCHEMBL4635894 0.77 OPRD1 (0.44) CES2CES1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101384581-B Benzoyl-piperidine derivatives as 5HT2/D3 modulators HOFFMANN LA ROCHE 2013-09-18 CN disclosed
US-8415350-B2 Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors HOFFMANN-LA ROCHE INC. (US) 2013-04-09 US disclosed
US-20120004208-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS GOBBI LUCA (CH) 2012-01-05 US disclosed
US-8039490-B2 Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors HOFFMANN-LA ROCHE INC. (US) 2011-10-18 US disclosed
CN-101384581-A Benzoyl-piperidine derivatives as 5HT2/D3 modulators HOFFMANN LA ROCHE (CH) 2009-03-11 CN disclosed
EP-1987019-A1 BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
US-20070197531-A1 Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 US disclosed
WO-2007093540-A1 BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004208-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HTR2A, HTR3A, HTR2C CES2 877/4885CES1 3357/4885PTPN1 2184/4885
US-20070197531-A1 Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors HTR2A, HTR3A, HTR2C CES2 877/4885CES1 3357/4885PTPN1 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.